The NF-κB/Rel family of transcription factors in oncogenic transformation and apoptosis

Mutation Research - Reviews in Mutation Research

Volumn 437, Issue 3, 1999, Pages 231-243

  De Martin, Rainer ^a   Schmid, Johannes A ^a   Hofer Warbinek, Renate ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Programmed cell death; Stress response; Transcriptional regulation

Indexed keywords

CELL ADHESION MOLECULE; CELL SURFACE RECEPTOR; CYCLOHEXIMIDE; CYTOKINE; DACTINOMYCIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN KAPPA CHAIN; INTERLEUKIN DERIVATIVE; MANGANESE SUPEROXIDE DISMUTASE; MITOGEN ACTIVATED PROTEIN KINASE; SALICYLATE SODIUM; TRANSCRIPTION FACTOR;

APOPTOSIS; CARCINOGENESIS; CELL CYCLE; GENE CONTROL; GENE EXPRESSION; HODGKIN DISEASE; HUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; STRESS; TRANSCRIPTION REGULATION; ANIMAL; CELL DIVISION; CELL TRANSFORMATION; GENE EXPRESSION REGULATION; GENETICS; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; CELL DIVISION; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; NF-KAPPA B; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 0032737937     PISSN: 13835742     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1383-5742(99)00089-7     Document Type: Review

References (98)

1. Sen R., Baltimore D. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell. 46:1986;705-716.
2. Baeuerle P., Baltimore D. NF-κB: ten years after. Cell. 87:1996;13-20.
3. Siebenlist U. NFκB/IκB proteins. Their role in cell growth, differentiation and development. Biochem. Biophys. Acta. 1332:1997;R7-R13.
4. Karin M. The NF-κB activation pathway: its regulation and role in inflammation and cell survival. Cancer J. Sci. Am. 4:1998;S92-S99.
5. Kunsch C., Ruben S.M., Rosen C.A. Selection of optimal kappa B/Rel DNA-binding motifs: interaction of both subunits of NF-κB with DNA is required for transcriptional activation. Mol. Cell. Biol. 12:1992;4412-4421.
6. Ghosh G., van Duyne G., Ghosh S., Sigler P.B. Structure of NF-κB p50 homodimer bound to a kappa B site. Nature. 373:1995;303-310.
7. Cramer P., Larson C.J., Verdine G.L., Müller C.W. Structure of the human NF-κB p52 homodimer-DNA complex at 2.1 A resolution. EMBO J. 16:1997;7078-7090.
8. Chen F.E., Huang D.B., Chen Y.Q., Ghosh G. Crystal structure of p50/p65 heterodimer of transcription factor NF-κB bound to DNA. Nature. 391:1998;410-413.
9. Chen Y.Q., Ghosh S., Ghosh G. A novel DNA recognition mode by the NF-κB p65 homodimer. Nat. Struct. Biol. 5:1998;67-73.
10. Belich M., Salmeron A., Johnston L.H., Ley S.C. Tpl-2 kinase regulates the proteolysis of the NF-κB-inhibitory protein NF-κB1 p105. Nature. 397:1999;363-368.
11. Franzoso G., Bours V., Park S., Tomita-Yamaguchi M., Kelly K., Siebenlist U. The candidate oncoprotein Bcl-3 is an antagonist of p50/NF-κB-mediated inhibition. Nature. 359:1992;339-342.
12. Huxford T., Huang D.B., Malek S., Ghosh G. The crystal structure of the IκBα/NF-κB complex reveals mechanisms of NF-κB inactivation. Cell. 95:1998;759-770.
13. Eder J. Tumour necrosis factor alpha and interleukin 1 signalling: do MAPKK kinases connect it all? Trends Pharmacol. Sci. 18:1998;319-322.
14. Malinin N.L., Boldin M.P., Kovalenko A.V., Wallach D. MAP3K-related kinase involved in NF-κB induction by TNF, CD95 and IL-1. Nature. 385:1997;540-544.
15. DiDonato J.A., Hayakawa M., Rothwarf D.M., Zandi E., Karin M. A cytokine-responsive IκB kinase that activates the transcription factor NF-κB. Nature. 388:1997;548-554.
16. Mercurio F., Zhu H., Murray B.W., Shevchenko A., Bennet B.L., Li J.W., Young D.B., Barbosa M., Mann M., Manning A., Rao A. IKK-1 and IKK-2: cytokine-activated IκB kinases essential for NF-κB activation. Science. 278:1997;860-866.
17. Regnier C.H., Song H.Y., Gao X., Goeddel D.V., Cao Z., Rothe M. Identification and characterization of an IκB kinase. Cell. 90:1997;373-383.
18. Woronicz J.D., Gao X., Cao Z., Rothe M., Goeddel D.V. IκB kinase-β: NF-κB activation and complex formation with IκB kinase-α and NIK. Science. 278:1997;866-869.
19. Zandi E., Rothwarf D.M., Delhase M., Hayakawa M., Karin M. The IκB kinase complex (IKK) contains two kinase subunits, IKKα and IKKβ, necessary for IκB phosphorylation and NF-κB activation. Cell. 91:1997;243-252.
20. Takeda K., Takeuchi O., Tsujimura T., Itami S., Adachi O., Kawai T., Sanjo H., Yoshikawa K., Terada N., Akira S. Limb and skin abnormalities in mice lacking IKKα Science. 284:1999;313-316.
21. Hu Y., Baud V., Delhase M., Zhang P., Deerinck T., Ellisman M., Johnson R., Karin M. Abnormal morphogenesis but intact IKK activation in mice lacking the IKKα subunit of IκB kinase. Science. 284:1999;316-320.
22. Li Q., Van Antwerp D., Mercurio F., Lee K.F., Verma I.M. Severe liver degeneration in mice lacking the IκB kinase 2 gene. Science. 284:1999;321-325.
23. Rothwarf D.M., Zandi E., Natoli G., Karin M. IKK-γ is an essential regulatory subunit of the IκB kinase complex. Nature. 395:1998;297-300.
24. Yamaoka S., Courtois G., Bessia C., Whiteside S.T., Weil R., Agou F., Kirk H.E., Kay R.J., Israel A. Complementation cloning of NEMO, a component of the IκB kinase complex essential for NF-κB activation. Cell. 93:1998;1231-1240.
25. Cohen L., Henzel W.J., Baeuerle P.A. IKAP is a scaffold protein of the IκB kinase complex. Nature. 395:1998;292-296.
26. Zhong H., SuYang H., Erdjument Bromage H., Tempst P., Ghosh S. The transcriptional activity of NF-κB is regulated by the IκB-associated PKAc subunit through a cyclic AMP-independent mechanism. Cell. 89:1997;413-424.
27. Yaron A., Hatzubai A., Davis M., Lavon I., Amit S., Manning A.M., Andersen J.S., Mann M., Mercurio F., Ben-Neriah Y. Identification of the receptor component of the IκBα-ubiquitin ligase. Nature. 396:1998;590-594.
28. Winston J.T., Strack P., Beer-Romero P., Chu C.Y., Elledge S.J., Harper J.W. The SCFβ-TrCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IκBα and β-catenin and stimulates IκBα ubiquitination in vitro. Genes Dev. 13:1999;270-283.
29. Spencer E., Jiang J., Chen Z.J. Signal-induced ubiquitination of IκBα by the F-box protein Slimb/β-TrCP. Genes Dev. 13:1999;284-294.
30. Beg A.A., Sha W.C., Bronson R.T., Baltimore D. Constitutive NF-κB activation, enhanced granulopoiesis, and neonatal lethality in IκBα-deficient mice. Genes Dev. 9:1995;2736-2746.
31. Klement J.F., Rice N.R., Car B.D., Abbondanzo S.J., Powers G.D., Bhatt P.H., Chen C.H., Rosen C.A., Stewart C.L. IκBα deficiency results in a sustained NF-κB response and severe widespread dermatitis in mice. Mol. Cell. Biol. 16:1996;2341-2349.
32. Wang D., Baldwin A.S. Activation of nuclear factor-κB-dependent transcription by tumor necrosis factor-α is mediated through phosphorylation of RelA/p65 on serine 529. J. Biol. Chem. 273:1998;29411-29416.
33. de Martin R., Vanhove B., Cheng Q., Hofer E., Csizmadia V., Winkler H., Bach F.H. Cytokine-inducible expression in endothelial cells of an IκBα-like gene is regulated by NF-κB. EMBO J. 12:1993;2773-2779.
34. Cheng Q., Cant C.A., Moll T., Hofer-Warbinek R., Wagner E., Birnstiel M.L., Bach F.H., de Martin R. NK-κB subunit-specific regulation of the IκBα promoter. J. Biol. Chem. 269:1994;13551-13557.
35. Le Bail O., Schmidt-Ullrich R., Israel A. Promoter analysis of the gene encoding the IκBα/MAD3 inhibitor of NF-κB: positive regulation by members of the Rel/NF-κB family. EMBO J. 12:1993;5043-5049.
36. Zabel U., Baeuerle P.A. Purified human IκB can rapidly dissociate the complex of the NF-κB transcription factor with its cognate DNA. Cell. 61:1990;255-265.
37. Arenzana-Seisdedos F., Thompson J., Rodriguez M.S., Bachelerie F., Thomas D., Hay R.T. Inducible nuclear expression of newly synthesized IκBα negatively regulates DNA-binding and transcriptional activities of NF-κB. Mol. Cell. Biol. 15:1995;2689-2696.
38. K. Tran, M. Merika, D. Thanos, Distinct functional properties of IκBα and IκBβ, Mol. Cell. Biol. (1997) 5386-5399.
39. Delhase M., Hayakawa M., Chen Y., Karin M. Positive and negative regulation of IκB kinase activity through IKKβ subunit phosphorylation. Science. 284:1999;309-313.
40. Cooper J.T., Stroka D.M., Brostjan C., Palmetshofer A., Bach F.H., Ferran C. A20 expression inhibits endothelial cell activation. Transplant. Proc. 29:1997;881.
41. Hu X., Yee E., Harlan J.M., Wong F., Karsan A. Lipopolysaccharide induces the antiapoptotic molecules, A1 and A20, in microvascular endothelial cells. Blood. 92:1998;2759-2765.
42. Wang C.Y., Mayo M.W., Korneluk R.G., Goeddel D.V., Baldwin A.S. NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science. 281:1998;1680-1683.
43. Stehlik C., de Martin R., Kumabashiri I., Schmid J.A., Binder B.R., Lipp J. NF-κB-regulated X-chromosome-linked iap gene expression protects endothelial cells from tumor necrosis factor α-induced apoptosis. J. Exp. Med. 188:1998;211-216.
44. Theilen G.H., Zeigel R.F., Twiehaus M.J. Biological studies with RE virus (strain T) that induces reticuloendotheliosis in turkeys, chickens, and Japanese quail. J. Natl. Cancer Inst. 37:1966;731-743.
45. Ballard D.W., Walker W.H., Doerre S., Sista P., Molitor J.A., Dixon E.P., Peffer N.J., Hannink M., Greene W.C. The v-rel oncogene encodes a kappa B enhancer binding protein that inhibits NF-κB function. Cell. 63:1990;803-814.
46. Kabrun N., Hodgson J.W., Doemer M., Mak G., Franza B.R.J., Enrietto P.J. Interaction of the v-Rel protein with an NF-κB DNA binding site. Proc. Natl. Acad. Sci. U. S. A. 88:1991;1783-1787.
47. Mosialos G., Gilmore T.D. v-Rel and c-Rel are differentially affected by mutations at a consensus protein kinase recognition sequence. Oncogene. 8:1993;721-730.
48. Gelinas C., Temin H.M. The v-rel oncogene encodes a cell-specific transcriptional activator of certain promoters. Oncogene. 3:1988;349-355.
49. Mosialos G., Hamer P., Capobianco A.J., Laursen R.A., Gilmore T.D. A protein kinase-A recognition sequence is structurally linked to transformation by p59v-rel and cytoplasmic retention of p68c-rel. Mol. Cell. Biol. 11:1991;5867-5877.
50. Carrasco D., Rizzo C.A., Dorfman K., Bravo R. The v-rel oncogene promotes malignant T-cell leukemia/lymphoma in transgenic mice. EMBO J. 15:1996;3640-3650.
51. Sachdev S., Hannink M. Loss of IkBa-mediated control over nuclear import and DNA binding enables oncogenic activation of c-Rel. Mol. Cell. Biol. 18:1998;5445-5456.
52. Gilmore T.D., Koedood M., Piffat K.A., White D.W. Rel/NF-κB/IκB proteins and cancer. Oncogene. 13:1996;1367-1378.
53. Bours V., Franzoso G., Azarenko V., Park S., Kanno T., Brown K., Siebenlist U. The oncoprotein Bcl-3 directly transactivates through kappa B motifs via association with DNA-binding p50B homodimers. Cell. 72:1993;729-739.
54. Michaux L., Dierlamm J., Wlodarska I., Bours V., Van den Berghe H., Hagemeijer A. t(14;19)/Bcl3 rearrangements in lymphoproliferative disorders: a review of 23 cases. Cancer Genet. Cytogenet. 94:1997;36-43.
55. Caamano J.H., Perez P., Lira S.A., Bravo R. Constitutive expression of Bc1-3 in thymocytes increases the DNA binding of NF-κB1 (p50) homodimers in vivo. Mol. Cell. Biol. 16:1996;1342-1348.
56. Ong S.T., Hackbarth M.L., Degenstein L.C., Baunoch D.A., Anastasi J., McKeithan T.W. Lymphadenopathy, splenomegaly, and altered immunoglobulin production in bcl3 transgenic mice. Oncogene. 16:1998;2333-2343.
57. Ishikawa H., Carrasco D., Claudio E., Ryseck R.P., Bravo R. Gastric hyperplasia and increased proliferative responses of lymphocytes in mice lacking the COOH-terminal ankyrin domain of NF-κB2. J. Exp. Med. 186:1997;999-1014.
58. Ryseck R.P., Bull P., Takamiya M., Bours V., Siebenlist U., Dobrzanski P., Bravo R. RelB, a new Rel family transcription activator that can interact with p50-NF-κB. Mol. Cell. Biol. 12:1992;674-684.
59. Weih F., Durham S.K., Barton D.S., Sha W.C., Baltimore D., Bravo R. Both multiorgan inflammation and myeloid hyperplasia in RelB-deficient mice are T cell dependent. J. Immunol. 157:1996;3974-3979.
60. Snapper C.M., Rosas F.R., Zelazowski P., Moorman M.A., Kehry M.R., Bravo R., Weih F. B cells lacking RelB are defective in proliferative responses, but undergo normal B cell maturation to Ig secretion and Ig class switching. J. Exp. Med. 184:1996;1537-1541.
61. Bargou R.C., Emmerich F., Krappmann D., Bommert K., Mapara M.Y., Arnold W., Royer H.D., Grinstein E., Greiner A., Scheidereit C., Doerken B. Constitutive nuclear factor-κB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J. Clin. Invest. 100:1997;2961-2969.
62. Wood K.M., Roff M., Hay R.T. Defective IκBα in Hodgkin cell lines with constitutively active NF-κB. Oncogene. 16:1998;2131-2139.
63. Krappmann D., Emmerich F., Kordes U., Scharschmidt E., Dörken B., Scheidereit C. Molecular mechanisms of constitutive NF-κB/Rel activation in Hodgkin/Reed-Sternberg cells. Oncogene. 18:1999;943-953.
64. Seitz C.S., Lin Q., Deng H., Khavari P.A. Alterations in NF-κB function in transgenic epithelial tissue demonstrate a growth inhibitory role for NF-κB. Proc. Natl. Acad. Sci. USA. 95:1998;2307-2312.
65. Kaltschmidt B., Kaltschmidt C., Hehner S.P., Droge W., Schmitz M.L. Repression of NF-κB impairs HeLa cell proliferation by functional interference with cell cycle checkpoint regulators. Oncogene. 18:1999;3213-3225.
66. Hinz M., Krappmann D., Eichten A., Heder A., Scheidereit C., Strauss M. NF-κB function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition. Mol. Cell. Biol. 19:1999;2690-2698.
67. Guttridge D.C., Albanese C., Reuther J.Y., Pestell R.G., Baldwin A.S. NF-κB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol. Cell. Biol. 19:1999;5785-5799.
68. Baldwin A.S.J., Azizkhan J.C., Jensen D.E., Beg A.A., Coodly L.R. Induction of NF-κB DNA-binding activity during the G0-to-G1 transition in mouse fibroblasts. Mol. Cell. Biol. 11:1991;4943-4951.
69. Kuida K., Zheng T.S., Na S., Kuan C., Yang D., Karasuyama H., Rakic P., Flavell R.A. Decreased apoptosis in the brain and premature lethality in CPP32-deficient mice. Nature. 384:1996;368-372.
70. Raff M. Cell suicide for beginners. Nature. 396:1998;119-122.
71. Van Antwerp D.J., Martin S.J., Verma I.M., Green D.R. Inhibition of TNF-induced apoptosis by NF-κB. Trends Cell Biol. 8:1998;107-111.
72. Baichwal V.R., Baeuerle P.A. Activate NF-κB or die? Curr. Biol. 7:1997;R94-R96.
73. Cardone M.H., Salvesen G.S., Widmann C., Johnson G., Frisch S.M. The regulation of anoikis: MEKK-1 activation requires cleavage by caspases. Cell. 90:1997;315-323.
74. Reuther J.Y., Baldwin A.S. Apoptosis promotes a caspase-induced amino-terminal truncation of IκBα that functions as a stable inhibitor of NF-κB. J. Biol. Chem. 274:1999;20664-20670.
75. LaCasse E.C., Baird S., Korneluk R.G., MacKenzie A.E. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene. 17:1998;3247-3259.
76. Grilli M., Memo M. Possible role of NF-κB and p53 in the glutamate-induced pro-apoptotic neuronal pathway. Cell Death Differ. 6:1999;22-27.
77. Dumont A., Hehner S.P., Hofmann T.G., Ueffing M., Droege W., Schmitz M.L. Hydrogen peroxide-induced apoptosis is CD95-independent, requires the release of mitochondria-derived reactive oxygen species and the activation of NF-κB. Oncogene. 18:1999;747-757.
78. Beg A.A., Baltimore D. An essential role for NF-κB in preventing TNF-α-induced cell death. Science. 274:1996;782-784.
79. Wang C.Y., Mayo M.W., Baldwin A.S.J. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science. 274:1996;784-787.
80. Van Antwerp D.J., Martin S.J., Kafri T., Green D.R., Verma I.M. Suppression of TNF-α-induced apoptosis by NF-κB. Science. 274:1996;787-789.
81. Higgins K.A., Perez J.R., Coleman T.A., Dorshkind K., McComas W.A., Sarmiento U.M., Rosen C.A., Narayanan R. Antisense inhibition of the p65 subunit of NF-κB blocks tumorigenicity and causes tumor regression. Proc. Natl. Acad. Sci. USA. 90:1993;9901-9905.
82. Wu M., Lee H., Bellas R.E., Schauer S.L., Arsura M., Katz D., FitzGerald M.J., Rothstein T.L., Sherr D.H., Sonenshein G.E. Inhibition of NF-κB/Rel induces apoptosis of murine B cells. EMBO J. 15:1996;4682-4690.
83. Erl W., Hansson G.K., de Martin R., Draude G., Weber K.S., Weber C. NF-κB regulates induction of apoptosis and inhibitor of apoptosis protein-1 expression in vascular smooth muscle cells. Circ. Res. 84:1999;668-677.
84. Tewari M., Dobrzanski P., Mohn K.L., Cressman D.E., Hsu J.C., Bravo R., Taub R. Rapid induction in regenerating liver of RL/IF-1 (an IκB that inhibits NF-κB, RelB-p50, and c-Rel-p50) and PHF, a novel kappa B site-binding complex. Mol. Cell. Biol. 12:1992;2898-2908.
85. Wong G.H., Elwell J.H., Oberley L.W., Goeddel D.V. Manganous superoxide dismutase is essential for cellular resistance to cytotoxicity of tumor necrosis factor. Cell. 58:1989;923-931.
86. Karsan A., Yee E., Kaushansky K., Harlan J.M. Cloning of human Bcl-2 homologue: inflammatory cytokines induce human A1 in cultured endothelial cells. Blood. 87:1996;3089-3096.
87. Kumar S., Baglioni C. Protection from tumor necrosis factor-mediated cytolysis by overexpression of plasminogen activator inhibitor type-2. J. Biol. Chem. 266:1991;20960-20964.
88. Opipari A.W.J., Hu H.M., Yabkowitz R., Dixit V.M. The A20 zinc finger protein protects cells from tumor necrosis factor cytotoxicity. J. Biol. Chem. 267:1992;12424-12427.
89. Grumont R.J., Rourke I.J., Gerondakis S. Rel-dependent induction of A1 transcription is required to protect B cells from antigen receptor ligation-induced apoptosis. Genes Dev. 13:1999;400-411.
90. Bours V., Dejardin E., Goujon-Letawe F., Merville M.P., Castronovo V. The NF-κB transcription factor and cancer: high expression of NF-κB- and IκB-related proteins in tumor cell lines. Biochem. Pharmacol. 47:1994;145-149.
91. Tulchinsky E., Prokhortchouk E., Georgiev G., Lukanidin E. A κB-related binding site is an integral part of the mts1 gene composite enhancer element located in the first intron of the gene. J. Biol. Chem. 272:1997;4828-4835.
92. Zhou G., Kuo M.T. NF-κB-mediated induction of mdr1b expression by insulin in rat hepatoma cells. J. Biol. Chem. 272:1997;15174-15183.
93. Lelkes P.I., Hahn K.L., Sukovich D.A., Karmiol S., Schmidt D.H. On the possible role of reactive oxygen species in angiogenesis. Adv. Exp. Med. Biol. 454:1998;295-310.
94. Royds J.A., Dower S.K., Qwarnstrom E.E., Lewis C.E. Response of tumour cells to hypoxia: role of p53 and NF-κB. Mol. Pathol. 51:1998;55-61.
95. Yoshida A., Yoshida S., Hata Y., Khalil A.K., Ishibashi T., Inomata H. The role of NF-κB in retinal neovascularization in the rat. Possible involvement of cytokine-induced neutrophil chemoattractant (CINC), a member of the interleukin-8 family. J. Histochem. Cytochem. 46:1998;429-436.
96. Patterson C., Perrella M.A., Hsieh C.M., Yoshizumi M., Lee M.E., Haber E. Cloning and functional analysis of the promoter for KDR/flk-1, a receptor for vascular endothelial growth factor. J. Biol. Chem. 270:1995;23111-23118.
97. Wrann M., Bodmer S., de Martin R., Siepl C., Hofer Warbinek R., Frei K., Hofer E., Fontana A. T cell suppressor factor from human glioblastoma cells is a 12.5-kd protein closely related to transforming growth factor-β EMBO J. 6:1987;1633-1636.
98. Devalaraja M.N., Wang D.Z., Ballard D.W., Richmond A. Elevated constitutive IκB kinase activity and IκBα phosphorylation in Hs294T melanoma cells lead to increased basal MGSA/GRO-α transcription. Cancer Res. 59:1999;1372-1377.